Medical Advocates for Social Justice

   Medical Advocates for Social Justice

  Conference Highlights:
Select Conference Abstracts and Posters
from the

   

 


 

 		1st European HIV Drug Resistance
Workshop
Cercle Municipal, Luxembourg




 March 06- 08, 2003		  
 
Main New/Newsworthy  Conference Updates : Main Page Home

Last Update:  February 21, 2007  

Recent Additions
Date   Format   Document
July 17   Presentation   Indinavir/Ritonavir 800/200 mg bid based regimen in multi-experienced
HIV positive patients with extensive drug resistance.
 
         
July 15   Abstract   Estimating effective drug combinations against drug-resistant mutants
from genotypes
         
July 07   Abstract   The impact of concomitant antiblastic chemotherapy and HAART on HIV-viraemia
and resistance profile in HIV-infected patients with non-Hodgkin's lymphoma 
Drug Data
HAART: General Data
 
  The impact of concomitant antiblastic chemotherapy and HAART on HIV-viraemia and resistance profile in HIV-infected patients with non-Hodgkin's lymphoma 
C Simonelli, S Zanussi, R.Cinelli, et al.
Abstract

ARV Drug Class: General Data

Fusion Inhibitors

  CONFERENCE PDF POSTER
Quantitative assessment of resistance to fusion inhibitors in a replicative Phenotyping assay.
V Brondani, F Hamy, T  Klimkait
 Poster

Protease Inhibitors

  Protease inhibitors cross-resistance
F Maggiolo, A Callegaro, D Ripamonti, et al.
Abstract
 
Distinct cross-resistance profiles of the new protease inhibitors (PI) Amprenavir, Lopinavir, and Atazanavir in a panel of clinical samples
 B Schmid, T Schnell , G Moschik, et al
Abstract

NNRTIs
 
  PDF POSTER
First Low Detectable Viremia (FDV) and Resistance-Associated Mutation under Non Nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen
JM Chapplain, A Ruffault , N Kerriguy, et al
PDF Poster

ARV Drug-Specific Data

Abacavir

  PDF POSTER
Reverse transcriptase mutational patterns of HIV-1 clinical isolates from patients treated with Abacavir in different drug combinations
M Daeumer, N Beerenwinkel, S Sierra. et al.
PDF Poster
 
PDF POSTER
Genotypic resistance profile in treatment-experienced HIV-infected individuals after Abacavir and Efavirenz salvage regimen
A. Vallejo, M. Olivera, A. Rubio, et al.
PDF Poster

Amprenavir

  Distinct cross-resistance profiles of the new protease inhibitors (PI) Amprenavir, Lopinavir, and Atazanavir in a panel of clinical samples
 B Schmid, T Schnell , G Moschik, et al
Abstract

Atazanavir

  PDF POSTER
Emergence of Unique I50L Substitution in Response to Atazanavir Treatment in Naive and PI Experienced Patients 
R Colonno, R Rose, J Froborg
 Poster

Enfuvirtide

  PDF POSTER
Enfuvirtide Baseline (BL) and on-Treatment Susceptibility:Week 24 analysis in TORO 1 and TORO 2 -
N Cammack, M Greenburg, T Melby, et al
 PDF Poster
 
PDF POSTER
Uncommon gp41 variants at residue positions critical for Enfuvirtide (T-20) resistance in Enfuvirtide-naïve patients infected with subtype B and NON-B HIV-1.
Roman F, Gonzalez D, Lambert C , et al.
PDF Poster

PDF POSTER
Quantitative assessment of resistance to fusion inhibitors in a replicative Phenotyping assay.
V Brondani, F Hamy, T  Klimkait
 PDF Poster
 

Indinavir
 
  POWER-POINT PRESENTATION
Indinavir/Ritonavir 800/200 mg bid based regimen in multi-experienced HIV positive patients with extensive drug resistance.
A Vincenti, L Vatteroni, F Pacini, A Scasso
 Presentation
 

Lopinavir
 
 
PDF POSTER
 Cumulative Development of PI and NRTI Resistance in HIV-Infected Subjects receiving Lopinavir/Ritonavir or Nelfinavir as Initial Therapy
D Kempf, M King, E Bauer, et al
 PDF Poster
 
PDF POSTER
 SOKRATES: Prospective Clinical Trials to Investigate the Evolution of Protease Resistance During Lopinavir/Ritonavir Treatment
RC Stevens, P. Cernohous, M. King, et al
 PDF Poster
 
Distinct cross-resistance profiles of the new protease inhibitors (PI) Amprenavir, Lopinavir, and Atazanavir in a panel of clinical samples
 B Schmid, T Schnell , G Moschik, et al
Abstract

Nevirapine
 
  PDF POSTER
HIV-1 pol gene diversity and archived Nevirapine resistance mutation in pregnant women in Rwanda
J Servais , C Lambert , E Karita, et al
 PDF Poster

Saquinavir

  PDF POSTER
Response to Boosted-Saquinavir (SQV) Containing HAART in PI-Experienced Patients: Comparison of B Versus Non-B Subtypes
S De Wit , R Boulmé , B Poll, et al.
PDF Poster

Stavudine
 
  PDF POSTER
Very high incidence of K65R detected in antiretroviral-naive patients failing randomised treatment with a triple nucleoside regimen consisting of Stavudine, Abacavir and Didanosine
BT Røge, TL. Katzenstein, N Obel, et al
PDF Poster

Tenofovir
 
  PDF POSTER
Phenotypic resistance to Tenofovir of a multinucleoside resistant HIV-1 strain containing
Q151M in association with other specific mutations
K Van Laethem, M Witvrouw, C Pannecouque, et al
PDF Poster

Zidovudine
 
  CONFERENCE PDF POSTER
Some baseline ZDV resistance mutations may not predict drug failure in patients treated with ZDV/3TC/IDV
Duque , A Carvalho , C Morais, et al.
PDF Poster
Therapeutic Drug Monitoring
 
POWERPOINT POSTER
Quantitative assessment of resistance to fusion inhibitors in a replicative Phenotyping assay.
V Brondani, F Hamy, T  Klimkait
 Poster

CONFERENCE PDF POSTER
Development of a novel rapid assay to determine HIV-1 fitness-differences in patients failing protease inhibitor treatment
N van Maarseveen, D de Jong, A Smits, et al
 PDF Poster

CONFERENCE PDF POSTER
The Prognostic Value to Predict Virological Outcomes of 14 Distinct SystemsUsed to Interpret the Results of Genotypic HIV-1 Drug Resistance Testing in Untreated Patients
A De Luca, A Cozzi-Lepri, CF Perno, et al
 PDF Poster
 
CONFERENCE PDF POSTER
The VirtualPhenotype : A Quantitative Prediction Of HIV Drug Susceptibility From Viral Genotype
L Bacheler, H van Marck, H Vermeiren, et al
PDF Poster
 
CONFERENCE PDF POSTER
Discrepant results between antiretroviral resistance mutations patterns by genotypic analysis (Stanford HIV-SEQ program) and virtual phenotype (VircoNET)
Pérez-Alvarez L, Carmona R, Muñoz M. et al
 PDF Poster
 
CONFERENCE PDF POSTER
Genotypic drug-resistance patterns in non-B HIV-1 strains from patients receiving ART in Dakar, Senegal.
L Vergne, CT Kane, C Lauren, .et al
 PDF Poster
 
Estimating effective drug combinations against drug-resistant mutants from genotypes
N Beerenwinkel, T Lengauer, M Däumer, et al   p
Abstract
Treatment Strategies
  PDF POSTER
Continuously Alternating Therapy (CAT): A New Option In Antiretroviral Salvage Therapy ?C
C. Weber, H. Stocker, M. Müller, et al.
PDF Poster
Main New/Newsworthy  Conference Updates : Main Page Home

Top od the Page

1st European HIV Drug Resistance Workshop
 Select Abstracts and Posters
 A Medical Advocates for Social Justice Update